Guggenheim Lifts PT on Regeneron Pharmaceuticals (REGN) to $815 From $810

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top most undervalued biotech stocks to buy now. Guggenheim analyst Yatin Suneja raised the firm’s price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $815 from $810 on August 4, keeping a Buy rating on the shares.

Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week

A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality.

The analyst told investors in a post-earnings note that the company’s fiscal Q2 performance exceeded investor expectations due to solid Dupixent sales and “a good performance from a struggling Eylea franchise.”

Suneja added that management made “some interesting comments on the call regarding BD strategy,” suggesting that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is now open to considering “differentiated later-stage opportunities in areas with high unmet medical need” compared to its previous focus on early-stage assets.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.